IP Library › Granted Patent US 9,227,928
Granted Patent B2
US 9,227,928 · App. 13/343,374 · Granted Jan 5, 2016

Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts

Inventors: Unni Santhosh (Chennai, IN); Annadurai Marimuthu Senthilkumar (Chennai, IN); Bodireddy Mohan Reddy (Chennai, IN); Rajendran Kamala (Chennai, IN); Mahender Rao Siripragada (Chennai, IN)
Assignee: AmDerma Pharmaceuticals, LLC
C07C303/06C07C303/22C07C309/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,227,928
App. No.
13/343,374
Granted
Jan 5, 2016
Kind
B2
Abstract

Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5 2,5-dihydroxybenzenesulfonic acid are provided.

Claims (14)

1. A crystalline form of potassium 2,5-dihydroxybenzenesulfonate having characteristic 2θ values of 8.8, 13.7, 15.6, 18.9, 21.4, 26.8, 27.7 and 30.3(±1).

2. The crystalline form of potassium 2,5-dihydroxybenzenesulfonate of claim 1 made by a process comprising the steps of

(i) sulfonation of hydroquinone of formula (II) using sulfuric acid to provide a compound of formula (III)

ii) treating the compound of formula (III) with potassium 2-ethylhexanoate; and

iii) precipitating the potassium 2,5-dihydroxybenzenesulfonate using ethyl acetate.

3. The crystalline form of potassium 2,5-dihydroxybenzenesulfonate of claim 2 , wherein the potassium 2,5-dihydroxybenzenesulfonate is achieved in a yield of at least 75%.

4. A crystalline form of potassium 2,5-dihydroxybenzenesulfonate having 2θ values of 8.8, 15.6, 17.7, 18.9, 21.4, 21.5, 26.8, 26.9, and 35.9(±1).

5. The crystalline form of potassium 2,5-dihydroxybenzenesulfonate of claim 4 crystallized from a water/solvent mixture.

6. The crystalline form of potassium 2,5-dihydroxybenzenesulfonate of claim 5 wherein the solvent is isopropyl alcohol.

7. The crystalline form of potassium 2,5-dihydroxybenzenesulfonate of claim 6 precipitated using ethyl acetate.

8. A crystalline form of potassium 2,5-dihydroxybenzenesulfonate having 2θ values of 15.6, 18.9, 21.3, 21.4, 27.7, and 30.3(±1).

9. The crystalline form of potassium 2,5-dihydroxybenzenesulfonate of claim 8 crystallized from a water/solvent mixture.

10. The crystalline form of potassium 2,5-dihydroxybenzenesulfonate of claim 9 wherein the solvent is acetone.

11. The crystalline form of potassium 2,5-dihydroxybenzenesulfonate of claim 10 precipitated using ethyl acetate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2014
From: ACTION MEDICINES, S.L.
To: AMDERMA PHARMACEUTICALS, LLC
Reel/Frame 034602/0495 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2012
From: SANTHOSH, UNNI; SENTHILKUMAR, ANNADURAI MARIMUTHU; REDDY, BODIREDDY MOHAN; KAMALA, RAJENDRAN; SIRIPRAGADA, MAHENDER RAO
To: ACTION MEDICINES, S.L.
Reel/Frame 029172/0479 →
Priority Claims (1)
IN 21/CHE/2008 · Jan 3, 2008 · national
Continuity (2)
Continuation 12811621
Related Publication 20120149938A1 · Jun 14, 2012